Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

236.00CHF
16 Jan 2018
Change (% chg)

CHF-8.40 (-3.44%)
Prev Close
CHF244.40
Open
CHF241.50
Day's High
CHF242.35
Day's Low
CHF234.50
Volume
4,612,399
Avg. Vol
1,722,688
52-wk High
CHF273.00
52-wk Low
CHF226.10

Select another date:

Fri, Jan 12 2018

Photo

Roche's star MS medicine Ocrevus wins EU approval

ZURICH The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.

UPDATE 1-Roche's star MS medicine Ocrevus wins EU approval

ZURICH, Jan 12 The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.

Roche's star MS medicine Ocrevus wins European approval

ZURICH, Jan 12 The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on sale in the United States.

BRIEF-Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

* SYAPSE ENTERS STRATEGIC COLLABORATION WITH ROCHE TO ADVANCE PRECISION MEDICINE IN ONCOLOGY

BRIEF-Roche Holding Ag Says ‍Roche And Ge Enter Partnership To Develop Integrated Digital Diagnostics​

* SAYS ‍ROCHE AND GE ENTER PARTNERSHIP TO DEVELOP INTEGRATED DIGITAL DIAGNOSTICS​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion

Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 bln

Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

UPDATE 2-Roche to buy U.S. cancer drugmaker Ignyta for $1.7 bln

Dec 22 Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday.

Roche to buy US cancer drugmaker Ignyta for $1.7 bln

Dec 22 Swiss drugmaker Roche said on Friday it would buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion.

BRIEF-Roche To Acquire Ignyta For $1.7 Bln

* IGNYTA INC SAYS ROCHE TO ACQUIRE IGNYTA FOR US$ 27.00 PER SHARE

Select another date: